Please see attached for edits.  I think I sent my original to the wrong address.  However please send this to Maria Walsh.

 

Many thanks

 

Colin

 

 

Colin

 

Do you have any edits re your presentation, if so they must be in by end of today.

 

Gill

-------------------------------------------------------
Gill Pilgrim
Administrative Secretary/Archivist
------------------------------------------------------

Xceleron Ltd
York Biocentre
Innovation Way
Heslington
York
YO10 5NY
United Kingdom

Tel No:  +44(0)1904 561561 
Fax No: +44(0)1904 561560

Email: gill.pilgrim@xceleron.co.uk

Visit our Web site at http://www.xceleron.co.uk

Important Notice

The information contained in this message may include privileged, proprietary or confidential information.  Please treat it with the same respect that you would expect for your own information.  If you have received it in error, we apologise, and ask that you contact the sender immediately and erase it from your computer.  Thank you for your co-operation.

 

From: Colin Garner
Sent: 26 October 2004 18:14
To: Gill Pilgrim; June Garner; Andrew Davidson
Subject: FW: Docket No 2004N-0432
Importance: High

 

 

Professor Colin Garner BPharm PhD DSc FRCPath

Chief Executive Officer

-----------------------------------

 

Xceleron Ltd

York Biocentre

Innovation Way

Heslington

York YO10 5NY

United Kingdom

 

Switchboard:    +44(0)1904 561561

Direct line:        +44(0)1904 561568

FAX:                +44(0)1904 561560

Email: colin.garner@xceleron.co.uk

 

Why not visit our Web site

 

http://www.xceleron.co.uk

 

Important Notice:

The information contained in this message may include privileged, proprietary or confidential information.  Please treat it with the same respect that you would expect for your own information.  If you have received it in error, we apologise, and ask that you contact the sender immediately and erase it from your computer.  Thank you for your co-operation.

 

 

-----Original Message-----
From: Walsh, Maria R [mailto:WALSH@cder.fda.gov]
Sent: 26 October 2004 18:06
To: 'Colin.Garner@xceleron.co.uk'
Subject: FW: Docket No 2004N-0432
Importance: High

 

Dr. Garner,

 

You are scheduled to present at the November 16th RDRC public meeting during the 2:45 - 4:00 pm public presentation period.  Your name will appear on the agenda as follows:

 

Colin Garner, PhD, DSc, FRCPath, CEO, Xceleron Ltd., U.K.

Please let me know if you have any edits by close of business November 1, 2004.

Thank you.

Maria 

Maria R. Walsh, RN, MS
Project Management Officer

FDA/CDER/OND
Office of Drug Evaluation III Immediate Office (HFD-103)
5600 Fishers Lane
Rockville, Maryland 20857
Phone: (301) 827-3139
Fax: (301) 480-3761
e-mail: walsh@cder.fda.gov

 

-----Original Message-----
From: Colin Garner [mailto:Colin.Garner@xceleron.co.uk]
Sent: Wednesday, October 13, 2004 8:31 AM
To: 'fdadockets@oc.fda.gov'
Subject: Docket No 2004N-0432
Importance: High

<<21 CFR Part 361 submission VO1 Garner Xceleron 16 November 2004.doc>>

Please find attached a request to attend and to present at the Public Meeting concerning 21 CFR Part 361 on 16^th November 2004. 

Could you kindly acknowledge receipt of this email and let me know if my attendance will be possible?

Yours sincerely

Professor Colin Garner BPharm PhD DSc FRCPath

Chief Executive Officer

-----------------------------------

Xceleron Ltd

York Biocentre

Innovation Way

Heslington

York YO10 5NY

United Kingdom

Switchboard:    +44(0)1904 561561

Direct line:    +44(0)1904 561568

FAX:            +44(0)1904 561560

Email: colin.garner@xceleron.co.uk

Why not visit our Web site

http://www.xceleron.co.uk

Important Notice:

The information contained in this message may include privileged, proprietary or confidential information.  Please treat it with the same respect that you would expect for your own information.  If you have received it in error, we apologise, and ask that you contact the sender immediately and erase it from your computer.  Thank you for your co-operation.